NasdaqGM - Nasdaq Real Time Price USD

I-Mab (IMAB)

1.3100
+0.0500
+(3.97%)
At close: May 30 at 4:00:00 PM EDT
1.2900
-0.02
(-1.53%)
After hours: May 30 at 5:16:11 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
632
-1,551
13,809.9496
Cost of Revenue
73,669
--
0
3,947.7918
7,284.4794
Gross Profit
48,440
--
3,899.7827
-36,061.6294
6,525.4703
Operating Expense
46,916
50,153
48,394
51,094
329,660.6580
Operating Income
-46,916
-50,153
-47,762
-52,645
-323,135.1877
Net Non Operating Interest Income Expense
8,649
7,486
9,294
4,954
3,346.8254
Other Income Expense
-5,160
-7,029
-43,749
-93,409
-46,490.0143
Pretax Income
-43,427
-49,696
-82,217
-141,100
-366,278.3766
Tax Provision
0
0
0
103
-494.8150
Net Income Common Stockholders
-9,063
-22,230
-207,729
-371,053
-365,783.5616
Diluted NI Available to Com Stockholders
-9,063
-22,230
-207,729
-371,053
-365,783.5616
Basic EPS
-0.12
-0.28
-2.33
-4.24
-4.82
Diluted EPS
-0.12
-0.28
-2.33
-4.24
-4.82
Basic Average Shares
81,384.1920
81,186.2490
88,654.0630
82,516.2140
75,959.5890
Diluted Average Shares
81,384.1920
81,186.2490
88,654.0630
82,516.2140
75,959.5890
Total Operating Income as Reported
-48,189
-51,426
-72,017
-53,078
-324,956.7782
Total Expenses
46,916
50,153
48,394
51,094
336,945.1374
Net Income from Continuing & Discontinued Operation
-9,063
-22,230
-207,729
-371,053
-365,783.5616
Normalized Income
-38,072
-44,341
-50,014
-119,692.2500
-377,120.5732
Interest Income
8,649
7,486
9,294
4,954
3,346.8254
Interest Expense
--
--
101.8537
1.3045
0
Net Interest Income
8,649
7,486
9,294
4,954
3,346.8254
EBIT
-46,916
-50,153
-47,762
-52,645
-366,278.3766
EBITDA
-46,916
-49,175
-46,701
-51,230
-360,922.9538
Reconciled Cost of Revenue
73,669
--
0
3,947.7918
7,284.4794
Reconciled Depreciation
53,863
978
1,061
1,415
5,355.4227
Net Income from Continuing Operation Net Minority Interest
-43,427
-49,696
-82,217
-141,203
-365,783.5616
Total Unusual Items Excluding Goodwill
-5,355
-5,355
-32,203
-28,681
11,352.3478
Total Unusual Items
-5,355
-5,355
-32,203
-28,681
11,352.3478
Normalized EBITDA
-41,561
-43,820
-14,498
-22,549
-372,275.3016
Tax Rate for Calcs
0
0
0
0.0003
0
Tax Effect of Unusual Items
0
0
0
-7,170.2500
15.3362
12/31/2021 - 1/17/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ZLAB Zai Lab Limited
30.14
-3.74%
 
ITOS iTeos Therapeutics, Inc.
10.02
-0.10%
 
CNTX Context Therapeutics Inc.
0.5771
-6.50%
 
PASG Passage Bio, Inc.
0.4363
-3.41%
 
ANRO Alto Neuroscience, Inc.
2.5800
-4.09%
 
CNTB Connect Biopharma Holdings Limited
0.8400
+5.00%
 
CCCC C4 Therapeutics, Inc.
1.2500
-5.30%
 
ORIC ORIC Pharmaceuticals, Inc.
8.17
+2.51%
 
ALXO ALX Oncology Holdings Inc.
0.4855
+3.92%
 
FGEN FibroGen, Inc.
0.2876
-9.59%